Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5736-5742

  Lamfers, Martine L M ^a   Grill, Jacques ^b   Dirven, Clemens M F ^a   Van Beusechem, Victor W ^a   Geoerger, Birgit ^b   Van Den Berg, Jaap ^a   Alemany, Ramon ^c   Fueyo, Juan ^d   Curiel, David T ^c   Vassal, Gilles ^b   Pinedo, Herbert M ^a   Vandertop, W Peter ^a   Gerritsen, Winald R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; INTEGRIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RECEPTOR;

ADENOVIRUS; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL VIABILITY; CLINICAL ARTICLE; DOSE RESPONSE; EMBRYO; FEMALE; GENE DELETION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR REGRESSION; TUMOR SPHEROID; TUMOR XENOGRAFT; VIRUS INFECTIVITY; VIRUS REPLICATION;

ADENOVIRIDAE; ADULT; AGED; ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; MALE; MICE; MICE, NUDE; MIDDLE AGED; OLIGOPEPTIDES; RECEPTORS, VIRUS; RECEPTORS, VITRONECTIN; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037109013     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Smith, E. R., and Chiocca, E. A. Oncolytic viruses as novel anticancer agents: Turning one scourge against another. Expert. Opin. Investig. Drugs, 9: 311-327, 2000.
2. Gromeier, M., and Wimmer, E. Viruses for the treatment of malignant glioma. Curr. Opin. Mol. Ther., 3: 503-508, 2001.
3. Andreansky, S., Soroceanu, L., Flotte, E. R., Chou, J., Markert, J. M., Gillespie, G. Y., Roizman, B., and Whitley, R. J. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res., 57: 1502-1509. 1997.
4. Bischoff, J. R., Kim, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
5. Ries, S., and Korn, W. M. ONYX-015: Mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer, 86: 5-11, 2002.
6. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y. X., Levin, V. A., Yung, W. K., and Kyritsis, A. P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 19: 2-12, 2000.
7. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kim, D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med., 6: 134-1139, 2000.
8. Collins, V. P. Genetic alterations in gliomas. J. Neuro-Oncol., 24: 37-38, 1995.
9. Asaoka, K., Tada, M., Sawamura, Y., Ikeda, J., and Abe, H. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J. Neurosurg., 92: 1002-1008, 2000.
10. Grill, J., Van Beusechem, V. W., Van Der Valk, P., Dirven, C. M., Leonhart, A., Pherai, D. S., Haisma, H. J., Pinedo, H. M., Curiel, D. T., and Gerritsen, W. R. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res., 7: 641-650, 2001.
11. Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T., and Alemany, R., A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res., 7: 120-126, 2001.
12. Bauerschmitz, G. J., Lam, J. T., Kanerva, A., Suzuki, K., Nettelbeck, D. M., Dmitriev, I., Krasnykh, V., Mikheeva, G. V., Barnes, M. N., Alvarez, R. D., Dall, P., Alemany, R., Curiel, D. T., and Hemminki, A. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res., 62, 1266-1270, 2002.
13. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kim, D. H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer., Nat. Med., 6: 879-885. 2000.
14. Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., and Kim, J. H. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther., 9: 1323-1333, 1998.
15. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kim, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
16. Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C., and Kim, D. H. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res., 60: 1193-1196, 2000.
17. Chen, Y., DeWeese, T., Dilley, J., Zhang, Y. Li, Y., Ramesh, N., Lee, J., PennathurDas, R., Radzyminski, J., Wypych, J., Brignetti, D., Scott, S., Stephens, J., Karpf, D. B., Henderson, D. R., and Yu, D. C. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res., 61: 5453-5460, 2001.
18. DeWeese, T. L., van der Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U., DeJong, R., Detorie, N., Rodriguez, R., Haulk, T., DeMarzo, A. M., Piantadosi, S., Yu, D. C., Chen, Y., Henderson, D. R., Carducci, M. A., Nelson, W. G., and Simons, J. W. A Phase I trial of cv706, a replication-competent. PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res., 61: 7464-7472, 2001.
19. Advani, S. J., Sibley, G. S., Song, P. Y., Hallahan, D. E., Kataoka, Y., Roizman, B., and Weichselbaum, R. R. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther., 5: 160-165, 1998.
20. Spear, M. A., Sun, F., Eling, D. J., Gilpin, E., Kipps, T. J., Chiocca, E. A., and Bouvet, M. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther., 7: 1051-1059, 2000.
21. Mohapatra, G., Kim, D. H., and Feuerstein, B. G. Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosomes Cancer, 13: 86-93, 1995.
22. Geoerger, B., Grill, J., Opolon, P., Morizet, J., Aubert, G., Terrier-Lacombe, M. J., Bressac De-Paillerets, B., Barrois, M., Feunteun, J., Kirn, D. H., and Vassal, G., Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res., 62: 764-772, 2002.
23. Darling, J. L. The in vivo biology of human brain tumors. In: D. G. T. Thomas (ed.), Neuro-oncology: Primary Malignant Brain Tumors, pp. 1-25. Baltimore, MD: Johns Hopkins University Press, 1990.
24. Bjerkvig, R., Tonnesen, A., Laemm, O. D., and Backlund, E. O. Multicellular tumor spheroids from human gliomas maintained in organ culture. J. Neurosurg., 72: 463-475, 1990.
25. Hsu, K. H., Lonberg-Holm, K., Alstein, B., and Crowell, R. L. A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J. Virol., 62: 1647-1652, 1988.
26. Grill, J., Lamfers, M. L. M., Van Beusechem, V. W., Dirven, C. M., Pherai, D. S., Kater, G. M., Van der Valk, P., Vogels, R., Vandertop, W. P., Pinedo, H. M., Curiel, D. T., and Gerritsen, W. R. The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol. Ther., in press. 2002.
27. Paulus, W., Baur, I., Schuppan, D., and Roggendorf, W. Characterization of integrin receptors in normal and neoplastic human brain. Am. J. Pathol., 143: 154-163, 1993.
28. Bello, L., Zhang, J., Nikas, D. C., Strasser, J. F., Villani, R. M., Cheresh, D. A., Carroll, R. S., and Black, P. M α(v)β3 and α(v)β5 integrin expression in meningiomas. Neurosurgery (Baltimore), 47: 1185-1195, 2000.
29. Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N., and Curiel, D. T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol., 72: 9706-9713, 1998.
30. Kirn, D. Clinical research results with d11520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther., 8: 89-98, 2001.
31. Chmura, S. J., Advani, S. J., Kufe, D. W., and Weichselbaum, R. R. Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat. Oncol. Investig., 7: 261-269, 1999.
32. Chung, S. M., Advani, S. J., Bradley, J. D., Kataoka, Y., Vashistha, K., Yan, S. Y., Markert, J. M., Gillespie, G. Y., Whitley, R. J., Roizman, B., and Weichselbaum, R. R. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther., 9: 75-80, 2002.